Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24, 13:00–16:00
AI·Intelligent Transformation: From Data Foundation to Scenario Value
Stay tuned
Conference Time: July 24, 13:00–16:00
13:30-13:35 Opening Remarks
Ruirong Yang: Partner, Marathon Venture (Beijing)
13:35-13:50 AI-Driven Development of New Quality Productive Forces in Healthcare & Investment Frontiers
Yinan Tang: Managing Director, Marathon Venture
13:50-14:05 From Data Foundation to Decision Intelligence: How InsRx OS Is Driving Professional Health Insurance into the Era of Intelligent Operations
Qiao Gong: Senior Vice President & Chief Product Officer, MediTrust Health
14:05-14:20 AI Combined with Organoids: Transforming Preclinical New Drug Discovery
Liuqi Huang: Vice President, bioGenous Biotechnology
14:20-14:35 Exploring the Frontiers of the Healthcare World Model
Du Zhao: Co-founder & Chief Financial Officer, SenseTime
14:35-14:50 SurgSmart: Connecting Data with Scenarios to Deliver Clinical Value
Xin Wang: Co-Founder, WithAI Innovation
14:50-15:05 Construction & Clinical Application of AI-Enabled Cardiovascular Chronic Disease Management System
Chuan Liu: Chief Medical Officer, HeartMed
15:05-16:00 Panel Discussion: Why Is China the Next Frontier for Global Medical AI?
Ruirong Yang: Partner, Marathon Venture (Beijing)
Yinan Tang: Managing Director, Marathon Venture
Qiao Gong: Senior Vice President & Chief Product Officer, MediTrust Health
Liuqi Huang: Vice President, bioGenous Biotechnology
Du Zhao: Co-founder & Chief Financial Officer, SenseTime
Xin Wang: Co-Founder, WithAI Innovation
Chuan Liu: Chief Medical Officer, HeartMed